Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver semaglutide. Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management. Woburn, Massachusetts-based develops a microarray patch (MAP) designed to deliver drugs. It features a soluble microarray with tips that gradually dissolve […]
ADA 2025
Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way
BTIG analysts said today that MiniMed, the Medtronic (NYSE:MDT) diabetes business, has some significant pipeline updates. Marie Thibault, Sam Eiber and Alexandra Pang shared notes from their meeting with Que Dallara, soon-to-be CEO of the to-be separated Diabetes unit, at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Among those updates, the company expects […]
Analysts expect Beta Bionics patch pump launch by 2027
BTIG analysts said today that Beta Bionics (Nasdaq:BBNX) expects to launch a new insulin patch pump system in the U.S. by the end of 2027. Marie Thibault, Sam Eiber and Alexandra Pang said the company revealed the new Mint system in a live demonstration at the American Diabetes Association’s 85th Scientific Sessions, outlining its plan […]
Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]
Study finds MannKind inhaled insulin safe, effective for children
New study results demonstrated the safety and efficacy of the MannKind Afrezza inhaled insulin offering for children with type 1 diabetes. Investigators presented findings from the INHALE-1 study as a symposium at the American Diabetes Association’s 85th Scientific Sessions. The data showed that inhaled insulin offers a safe and effective replacement for rapid-acting meal insulin […]
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely. That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation […]
Dexcom continues advances in AI for CGM, type 2 diabetes awareness
As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and […]
Tandem continues to deliver more options, benefits for those with diabetes
It’s been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn’t look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the flagship t:slim X2 and the Mobi miniature durable pump — that feature sophisticated software and connectivity to the market’s leading […]
Breaking: Sequel to launch twiist automated insulin delivery system next month
Sequel Med Tech announced at the American Diabetes Association’s 85th Scientific Sessions in Chicago that it plans to launch its twiist system in July. Dr. Joanna Mitri, the company’s chief medical officer, shared the update in a Product Theater session at the ADA Scientific Sessions in Chicago today. Mitri said the company plans to launch […]
Dexcom shares U.S. report on CGM benefits for type 2 diabetes
Dexcom (Nasdaq:DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S. The company released its report — “Dexcom State of Type 2 Report: Access and Attitudes Across the United States” — ahead of the American Diabetes Association’s 85th Scientific Sessions in Chicago. Findings provide insights into perceptions around […]
